Announcements - OBI Pharma 台灣浩鼎

2020.May.08

Supplementary statement for 2020 Shareholders’ Meeting (Change in location and new items)

2020.Apr.11

The active cancer immunotherapy OBI-822, Adagloxad Simolenin, has been granted by Ministry of Food and Drug Safety of South Korea to proceed Phase III human clinical study

2020.Apr.08

Due to the tense situation of Novel Coronavirus Disease (COVID-19), company decided to pause the recruitment of Global Phase III clinical study for 3 months and will restart recruitment when epidemic gets controlled.

2020.Mar.25

Updates on company’s negotiable securities for investors’ information

2020.Mar.13

Announcement on change of accountant due to internal adjustment of accounting firm

2020.Mar.13

The Board of Directors resolved to hold 2020 Annual General Meeting

2020.Mar.13

The board of directors have resolved not to distribute dividends for 2019

2020.Mar.13

Board of Directors approved the Company’s 2019 financial statement

2020.Mar.12

Clarification on News Article by Economy Daily News

2020.Mar.05

OBI Pharma Inc. to attend Investor Conference hosted by Masterlink Securities

News

Latest News

Events

Latest events